Risk of Rhabdomyolysis from 5-Alpha Reductase Inhibitors

    January 2018 in “ Pharmacoepidemiology and Drug Safety ”
    Blayne Welk, Eric McArthur, Michael Ordon … Amit X. Garg
    Studysummary In this study, 5-α reductase inhibitors were not significantly linked to increased rhabdomyolysis risk, but they may raise the risk of myopathy and myositis in men aged 66 and older.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on onlinelibrary.wiley.com →
    Discuss this study in the Community →

    Research cited in this study 5

    1. Association of Suicidality and Depression With 5α-Reductase Inhibitors JAMA Internal Medicine · 2017
    2. A Serious Side Effect of a Potentially Widely Used Cosmetic Product Clinical and Experimental Dermatology · 2015
    3. 5α-Reductases in Human Physiology: An Unfolding Story Endocrine Practice · 2012
    4. Finasteride-Induced Myalgia and HyperCKemia Journal of Clinical Neuromuscular Disease · 2008
    5. Reversible Severe Myopathy During Treatment with Finasteride Muscle & Nerve · 1997

    Related research 5

    1. Evaluation of the Therapeutic Effects of AGA Drugs by Measuring Finasteride, Dutasteride, and Dihydrotestosterone in Hair Clinica Chimica Acta · 2023
    2. Risk of Rhabdomyolysis from 5-Alpha Reductase Inhibitors Pharmacoepidemiology and Drug Safety · 2018
    3. What Do We Know About 5-Alpha Reductase Inhibitors? Surgical and Cosmetic Dermatology · 2018
    4. Dutasteride in Androgenetic Alopecia: An Update Current Clinical Pharmacology · 2017
    5. The Preventive and Therapeutic Efficacy of Finasteride and Dutasteride in TRAMP Mice The FASEB Journal · 2013